Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Key Points: Manufacturing CART19 by transfecting autologous T cells with messenger RNA is feasible. Targeting CD19+ B cells in cHL using nonviral RNA CART19 was well tolerated and resulted in transient responses in a pilot study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Electroporation remains the gold standard for IVT mRNA delivery into primary human T cells for in vitro and ex vivo applications.39,40,41,42”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [41]
In the citing paper
“Electroporation remains widely used for ex vivo CAR T cell engineering39,40,41,42 but poses hurdles for broad clinical adoption, including the need for leukapheresis, extensive cell manipulation, expansion, and reinfusion.75”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationBollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3179 · Cited by 181
Cited by
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Self-citationmRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
“CD19 CAR-T cells Hodgkin lymphoma NCT02277522 (I) Interval cyclophosphamide [162] 2014 Terminated (inability to meet enrollment goal) [163]”
BackgroundGene therapy for blood diseases
Kohn, D. B. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.016 · Cited by 39
Metadata
- Authors
- Svoboda, J., Rheingold, S. R., Gill, S. I., Grupp, S. A., Lacey, S. F., Kulikovskaya, I., Suhoski, M. M., Melenhorst, J. J., Loudon, B., Mato, A. R., Nasta, S. D., Landsburg, D. J., Youngman, M. R., Levine, B. L., Porter, D. L., June, C. H., & Schuster, S. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-09-06
- Volume
- 132
- Issue
- 10
- Pages
- 1022-1026
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2809520091
- Cited by
- 84
- References
- 3
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2018-03-837609
- The paper
- Svoboda, J., Rheingold, S. R., Gill, S. I., Grupp, S. A., Lacey, S. F., Kulikovskaya, I., Suhoski, M. M., Melenhorst, J. J., Loudon, B., Mato, A. R., Nasta, S. D., Landsburg, D. J., Youngman, M. R., Levine, B. L., Porter, D. L., June, C. H., & Schuster, S. J. (2018). Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2018-03-837609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.